Serum Interleukin-37 Concentrations and HBeAg Seroconversion in Chronic HBV Patients During Telbivudine Treatment
Serum Interleukin-37 Concentrations and HBeAg Seroconversion in Chronic HBV Patients During Telbivudine Treatment
复制标题
慢性乙型肝炎患者替比夫定治疗期间血清白细胞介素 37 浓度和 HBeAg 血清转化
DOI：
10.1089/jir.2013.0001
复制
发表时间：
2013-10-01
影响因子：
2.3
通讯作者：
Jiang, Yanfang
中科院分区：
文献类型：
--
作者：
Li, Cong;Ji, Huifan;Jiang, Yanfang
IL-37是一种新的抗炎细胞因子，通过限制免疫和炎症反应在感染期间保护组织免受损伤中发挥重要作用。本研究旨在观察替比夫定（LDT）治疗慢性乙型肝炎（B病毒）患者期间血清IL-37浓度和HBeAg血清转换。采用酶联免疫吸附试验（ELISA）检测40例HBeAg阳性慢性B型肝炎（CHB）患者、30例慢性丙型肝炎（CHC）患者（25例SR-CHC）和30例健康对照者（HC）血清IL-37水平。采用流式细胞仪微球阵列检测抗炎细胞因子IL-2和IL-10，并检测血清B表面抗原（HBsAg）、B核衣壳抗原（HBeAg）、丙氨酸转氨酶（ALT）、天冬氨酸转氨酶（AST）、HBV DNA和丙型肝炎病毒（HCV）RNA载量等临床指标。结果发现，高病毒载量的慢性HBV患者血清IL-37水平较高，但相关性无统计学意义。LDT治疗48周后HBeAg血清转换的CHB患者血清IL-37水平下降。CHC患者血清IL-37水平与SR-HCV、HC比较差异无统计学意义。CHB和CHC患者的抗炎细胞因子IL-2和IL-10水平低于HC，但CHB患者的IL-2水平在LDT治疗后升高。血清ALT（> 50 U/L）或AST（> 40 U/L）异常的CHB和CHC患者血清IL-37水平显著高于ALT（> 50 U/L）正常的CHB和CHC患者（P <0.05）。
IL-37 is a new anti-inflammatory cytokine that plays an important role in protecting against tissue injury during infections via limiting immune and inflammatory reactions. This study aimed at determining serum IL-37 concentrations and HBeAg seroconversion in chronic hepatitis B virus (HBV) patients during Telbivudine (LDT) treatment. The serum levels of IL-37 were determined using enzyme-linked immunosorbent assay (ELISA) in 40 chronic hepatitis B virus infection (CHB) patients (HBeAg positive), 30 chronic hepatitis C virus infection (CHC) patients [25 with spontaneously resolved hepatitis C virus (SR-CHC)], and 30 healthy controls (HCs). Anti-inflammatory cytokines such as IL-2 and IL-10 were measured using cytometric bead array, and the concentrations of clinical parameters such as serum hepatitis B surface antigen (HBsAg), hepatitis B nucleocapsid antigen (HBeAg), alanine transaminase (ALT), aspartate transaminase (AST), HBV DNA, and hepatitis C virus (HCV) RNA loads were measured. It was found that the serum levels of IL-37 were higher in chronic HBV patients with high virus loads, but the association was not statistically significant. The serum levels of IL-37 were decreased in HBeAg seroconverted CHB patients after 48 weeks of LDT treatment. The serum levels of IL-37 had no significant difference in CHC patients compared with SR-HCV and HCs. The levels of anti-inflammatory cytokine, IL-2 and IL-10, were lower in CHB and CHC patients than the HC, but IL-2 levels increased after LDT treatment in CHB patients. The concentrations of serum IL-37 in CHB and CHC patients with abnormal levels of serum ALT (>50U/L) or AST (>40U/L) were significantly higher than CHB, CHC patients with normal levels of ALT (